Childhood pre-B cell acute lymphoblastic leukemia with translocation t(1;19)(q21.1;p13.3) and two additional chromosomal aberrations involving chromosomes 1, 6, and 13: a case report

Abdulsamad Wafa, Manar As'sad, Thomas Liehr, Abdulmunim Aljapawe and Walid Al Achkar

Abstract

Background: The translocation t(1;19)(q23;p13), which results in the TCF3-PBX1 chimeric gene, is one of the most frequent rearrangements observed in B cell acute lymphoblastic leukemia. It appears in both adult and pediatric patients with B cell acute lymphoblastic leukemia at an overall frequency of 3 to 5%. Most cases of pre-B cell acute lymphoblastic leukemia carrying the translocation t(1;19) have a typical immunophenotype with homogeneous expression of CD19, CD10, CD9, complete absence of CD34, and at least diminished CD20. Moreover, the translocation t(1;19) correlates with known clinical high risk factors, such as elevated white blood cell count, high serum lactate dehydrogenase levels, and central nervous system involvement; early reports indicated that patients with translocation t(1;19) had a poor outcome under standard treatment.

Case presentation: We report the case of a 15-year-old Syrian boy with pre-B cell acute lymphoblastic leukemia with abnormal karyotype with a der(19)t(1;19)(q21.1;p13.3) and two yet unreported chromosomal aberrations: an interstitial deletion 6q12 to 6q26 and a der(13)t(1;13)(q21.1;p13). According to the literature, cases who are translocation t(1;19)-positive have a significantly higher incidence of central nervous system relapse than patients with acute lymphoblastic leukemia without the translocation. Of interest, central nervous system involvement was also seen in our patient.

Conclusions: To the best of our knowledge, this is the first case of childhood pre-B cell acute lymphoblastic leukemia with an unbalanced translocation t(1;19) with two additional chromosomal aberrations, del(6)(q12q26) and t(1;13)(q21.3;p13), which seem to be recurrent and could influence clinical outcome. Also the present case confirms the impact of the translocation t(1;19) on central nervous system relapse, which should be studied for underlying mechanisms in future.

Keywords: Acute lymphoblastic leukemia (ALL), t(1;19), TCF3-PBX1, Cytogenetics, Fluorescence in situ hybridization (FISH), Prognostic factors
Background
Translocation t(1;19)(q23;p13) is a repeatedly but overall rarely observed rearrangement in B cell acute lymphoblastic leukemia (B-ALL), and can be found in both adult and pediatric patients at an overall frequency of 3 to 5% [1, 2]. Most cases of pre-B-ALL carrying the translocation t(1;19) express a typical immunophenotype with homogeneous expression of CD19, CD10, CD9, complete absence of CD34, and reduced expression of CD20 [3]. This translocation can occur in two forms: a balanced or an unbalanced one. The unbalanced form of pre-B-ALL leads to a derivative of chromosome 19 [2]. Both the balanced and the unbalanced translocations t(1;19) result in the fusion of transcription factor 3 (TCF3) located in 19p13 with pre-B cell leukemia homeobox 1 (PBX1) in 1q23, to form a chimeric gene whose protein product alters, among other cellular processes, cell differentiation arrest [1]. Specifically, the fusion gene encodes for a transcription factor bearing the transactivation domain of TCF3 and the deoxyribonucleic acid (DNA)-binding domain of PBX1, which facilitates genes constitutive activation [4]. In addition, the fusion protein appears to have a dominant negative effect on the wild-type TCF3 activity. So both increased expression of PBX1 target genes and reduction in TCF3 activity are thought to be important in leukemogenesis [5].

Other partner genes of TCF3 include ZNF384 (12p13; prognosis unknown), NOL1 (12p13; prognosis unknown), an unknown partner gene in 13q14 (prognosis unknown), HLF (17q22; extremely poor prognosis), and FB1/TFPT (19q13.4; prognosis unknown) [6–8]. Moreover, the translocation t(1;19) correlates with known clinical high risk features, such as elevated white blood cell (WBC) count, high serum lactate dehydrogenase (LDH) levels, central nervous system (CNS) involvement, and poor outcome under standard treatment [9].

Here we report the clinical, G-banding, and molecular cytogenetic results obtained in a childhood patient with pre-B-ALL with an unbalanced translocation t(1;19) and two additional chromosomal aberrations.

Case presentation
On 22 May 2014, a 15-year-old Syrian boy without significant personal or familial history of malignancies presented to Al-Biruni University Hospital with a 1-month history of bleeding gums, fatigue, and pallor. He had no familial history of malignancies and no social and environmental history or exposure to toxins and animals. A physical examination revealed splenomegaly without lymph node involvement. An initial laboratory evaluation of peripheral blood (PB) revealed elevated WBC count of $56 \times 10^9/L$ with 94% of blasts cells, anemia (9.1 g/dL), and a thrombocytopenia ($123 \times 10^9/L$). His serum LDH value was 862 U/L (normal value up to 480 U/L). He was diagnosed as having pre-B-ALL according to the World Health Organization (WHO) classification. A biopsy of his bone marrow (BM) revealed hypercellular marrow (WBC count $155.3 \times 10^9/L$ with 94% of blasts cells).

He was referred (on 25 May 2014) to our Chromosomes Laboratory and Flow-cytometry Laboratory, Molecular Biology and Biotechnology Department, Atomic Energy Commission of Syria, for cytogentic and flow-cytometric analyses. He could be classified in a high risk group. Thus, he was supplied with German Multicenter Study Group for Adult Acute Lymphoblastic Leukemia (GMALL) protocol treatment after the initial diagnosis for 5 months. Unfortunately, due to the political situation in his home country he was given available drugs such as vincristine 1.4 mg/m$^2$, doxorubicin 25 mg/m$^2$, and methotrexate 20 mg/m$^2$. He responded to that treatment without any infiltrations in his BM; he received platelets and blood transfusions many times; his PB showed pancytopenia and neutropenia. The treatment was stopped before consolidation phase because his BM biopsy evaluation showed morphologic remission (8% blasts left); a cerebrospinal fluid test revealed abnormal cells; he also had a pulmonary infection. Approximately 5.5 months after initial diagnosis he died due to unknown causes while under treatment. No autopsy was performed because he died in his house. His parents agreed with the scientific evaluation of the case and a study was approved by the ethical committee of the Atomic Energy Commission, Damascus, Syria.

A chromosome analysis on a BM sample using GTG-banding according to standard procedures [10] was performed before his treatment started; it revealed a karyotype of 46,XY,del(6)(q?),der(13)t(1;13),der(19)t(1;19)[6]/46,XY,Y,del(6)(q?),der(19)t(1;19)[5]/47,XY,+i(1)(q?),del(6)(q?),der(19)t(1;19)[1]/46,XY[6] (Fig. 1). Karyotype was described according to the International System for Human Cytogenetic Nomenclature (ISCN) of 2013 [11].

Further studies were performed on BM sample using molecular cytogenetics (Fig. 2). We performed dual-color fluorescence in situ hybridization (D-FISH) with specific whole chromosome paint (WCP) probes for chromosomes 1, 6, 13, and 19 (MetaSystems, Altushein, Germany) [10], which did not provide any information on the cryptic translocations (data not shown), and array-proven high-resolution multicolor banding (aMCPB) [12], using probes for the corresponding chromosomes 1, 6, 13, and 19 involved according to GTG-banding (Fig. 2). Reverse transcriptase-polymerase chain reaction (RT-PCR) for E2A-PBX1 fusion transcripts was performed prior the treatment using specific primers previously described [13], confirmed the presence of the TCF3/PBX1 fusion (E2A/PBX1 transcript; 373-base pair band), most often identified in acute lymphoblastic
Fig. 1 GTG-banding revealed the following karyotype in 6/18 metaphases: 46,XY,del(6)(q?),der(13)t(1;13),der(19)t(1;19)[6]. All derivative chromosomes are marked and highlighted by arrow heads.

Fig. 2 Array-proven multicolor banding results are shown. The normal chromosomes (#) are depicted on the left side of each image and the derivative of the four chromosomes on the right side of normal chromosomes. The unstained regions when using chromosome-specific array-proven multicolor banding probe sets on the derivative chromosomes are shown in gray. a Different pseudocolor depictions for array-proven multicolor banding1 probe set revealed the breakpoints in derivative chromosomes 13, 19 and isochromosome 1q. b Array-proven multicolor banding6 uncovered the interstitial deletion in der(6). c Array-proven multicolor banding13 revealed that practically the whole short arm of chromosome 13 remained intact in the der(13). d The breakpoint on der(19) could be determined by multicolor banding19 probe set. # chromosome, der derivative chromosome, MCB multicolor banding.
leukemia (ALL; data not shown). Thus, the following final karyotype prior to treatment was determined using a fluorescence microscope (AxioImager.Z1 mot, Carl Zeiss Ltd, Hertfordshire, UK) equipped with appropriate filter sets to discriminate between a maximum of five fluorochromes plus the counterstain 4′,6-diamidino-2-phenylindole (DAPI). Image capture and processing were performed using an ISIS imaging system (MetaSystems): 46,XY,del(6)(q12q26),der(13)t(1;13)(q21.1;p13), der(19)t(1;19)(q21.1;p13.3)[6]/46,XY,del(6)(q12q26).der(19)t(1;19)(q21.1;p13.3)[5]/47,XY,+i(1)(q10),del(6)(q12q26),-der(19)t(1;19)(q21.1;p13.3)[1]/46,XY[6].

Immunophenotyping was performed on BM sample using a general panel of fluorescent antibodies against the following antigens typical for different cell lineages and cell types: CD1a, CD2, CD3, CD4, CD5, CD8, CD10, CD11b, CD11c, CD13, CD14, CD15, CD16, CD19, CD20, CD22, CD23, CD32, CD33, CD34, CD38, CD41a, CD45, CD55, CD57, CD64, CD103, CD117, CD123, CD138, CD209, CD235a, and CD243; in addition, antibodies to kappa and lambda light chains, IgD, surface-bound IgM (sIgM), and human leukocyte antigen-antigen D related (HLA-Dr) were tested. All antibodies were purchased from BD Biosciences (San Jose CA, USA). Samples were analyzed on a BD FACSCalibur™ flow cytometer. Autofluorescence, viability, and isotype controls were included. Flow cytometric data acquisition and analysis were conducted by BD Cellquest™ Pro software. Flow cytometric analysis of BM specimen characterized this case as pre-B-ALL according to WHO classifications. The abnormal cell population (94% of tested cells) was positive for CD45dim, CD19+, CD10-, HLA-DR-, and CD79a-. This cell population was negative for CD34, CD2, CD7, CD13, CD14, CD15, CD20, CD33, and CD117.

Discussion

According to the literature, the translocation t(1;19)(q23;p13) is a translocation that is repeatedly but, overall, rarely seen in B-ALL cases; it generates the translocation t(1;19)(q23;p13) can be observed in two principal forms [2, 15, 16]. Abnormalities of chromosome 1, such as complete or partial trisomies for the long arm, are known to arise during clonal evolution and can be observed as recurrent in hematologic malignancies [16–18].

The CKS1B gene mapped at 1q21 is a member of the highly conserved cyclin kinase subunit 1 (CKS1) protein family that interacts with cyclin-dependent kinases (Cdks) and plays a critical role in cell cycle progression [19]. CKS1B overexpression is correlated with low p27 expression and adverse survival in several human malignancies including gastric, colorectal, and oral squamous cell carcinomas [20–22] because of its critical role as a cell cycle regulator and its involvement in various human carcinomas.

This 6q12-22 area contains several genes with a known or suspected tumor-suppressing function including MAP3K7, for which a tumor-suppressive role for prostate epithelial cells has recently been demonstrated [23]. MAP3K7 is ubiquitary expressed and involved in various biological processes such as cell growth, differentiation, and apoptosis. MAP3K7 exerts these effects by interacting with a number of different signaling pathways and activator molecules [24–27].

In contrast to early reports on patients with translocation t(1;19) reporting a more adverse outcome for patients with balanced translocation compared with patients with an unbalanced translocation t(1;19) [28–30], more recent studies found no difference in event-free survival (EFS) among these two subgroups [30–32]. However, cases who are translocation t(1;19)-positive have a significantly higher incidence of CNS involvement in cases of relapse than patients with ALL without the translocation [30]; the St Jude’s group observed four patients with CNS relapse but no patients with BM relapse among 41 patients with translocation t(1;19) [33]. Also, Moorman et al. [34] reported six relapses in 50 patients with translocation t(1;19) of which three relapses involved the CNS. Moreover, CNS disease was found to be more common in patients with T cell acute lymphoblastic leukemia (T-ALL) compared with those with pre-B-ALL [35], and CNS involvement was associated with poor survival. Fielding et al. [36] showed as well that the outcome of relapsing patients was very poor, and that patients with T cell disease had only a 5% 5-year survival compared with 8% in those with B-ALL.

Additional cytogenetic abnormalities (ACAs) were observed in 63% (47 out of 2640, which is 1.8%, children
diagnosed as having B-ALL), with no significant differences between translocation t(1;19) and/or der(19)(t(1;19)-positive cases [37]. The most common ACAs were del(9p), i(9q), del(6q), and del(13q) [16, 20]. None of their 47 patients with translocation t(1;19) demonstrated concomitant aberrations of 13p13 and/or 6q12 to 6q26 regions. Thus, the clinical significance of an unbalanced translocation t(1;19)(q21.1p13.3) in our patient with a 13p13 translocation and/or del(6)(q12q26) is unclear. According to the literature the presence of ACAs has no significant impact on EFS or overall survival [35]. This observation is in line with findings from other recurrent leukemia-associated translocations, where ACAs seem to have no influence on prognosis [37, 38]. Still, the adverse outcome of the present case may be a hint that there are exceptions to that rule.

Patients with pediatric ALL with WBC counts of more than 50×10^9/l are considered to be at high risk of relapse and thus receive intensive treatment [39, 40]. In retrospective analysis, patients with hyperleukocytosis (WBC count >50×10^9/l) were significantly correlated with shorter survival times. The cytogenetic features were closely linked to the WBC and at least partly explain the prognostic value of WBC, although there is evidence that children with similar cytogenetic aberrations may have very different WBCs [41–43].

Conclusions
Here, we described the presence of two uncommon chromosomal aberrations, that is, del(6)(q12q26) and der(13)(t(1;13)(q21.1p13) in a case of childhood pre-B-ALL with unbalanced translocation t(1;19), which might suggest that special ACAs could have an adverse effect on clinical outcome, in contrast to what is widely discussed at present.

Abbreviations
ACAs: Additional cytogenetic abnormalities; ALL: Acute lymphoblastic leukemia; aMCB: Array-proven high-resolution multicolor banding; B-ALL: B cell acute lymphoblastic leukemia; BM: Bone marrow; Cdkc: Cyclin-dependent kinases; CK1: Cytokine kinase subunit 1; CNS: Central nervous system; DAPI: 4',6-diamidino-2-phenylindole; D-FISH: Dual-color fluorescence in situ hybridization; DNA: Deoxyribonucleic acid; EFS: Event-free survival; FISH: Fluorescence in situ hybridization; GMALL: German Multicenter Study Group for Adult Acute Lymphoblastic Leukemia; HLA-DR: Human leukocyte antigen-antigen D related; ISCN: International System for Human Cytogenetic Nomenclature; LDH: Lactate dehydrogenase; PB: Peripheral blood; PBX1: Pre-B cell leukemia homeobox 1; RT-PCR: Reverse transcriptase-polymerase chain reaction; sIgM: Surface-bound IgM; T-ALL: T cell acute lymphoblastic leukemia; TCF3: Transcription factor 3; WBC: White blood cell; WCP: Whole chromosome paint; WHO: World Health Organization

Acknowledgements
We thank Prof. I. Othman, the Director General of Atomic Energy Commission of Syria (AECS) and Dr N. Mirali, Head of Molecular Biology and Biotechnology Department for their support.

Funding
This work was supported by the Atomic Energy Commission of Syria (AECS).

Availability of data and materials
All data generated or analyzed during this study are included in this published article.

Authors’ contributions
AW, WA, and WA performed banding cytogenetics and provided the clinical data; AW and TL performed the molecular cytogenetic analyses; AA did the immunophenotyping; AW and TL drafted the paper and all authors worked on the final version of the paper. All authors read and approved the final manuscript.

Competing interests
The authors declare that they have no competing interests.

Consent for publication
Written informed consent was obtained from the patient’s legal guardian(s) for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.

Ethics approval and consent to participate
As all tests were done during diagnostic testing so in principle no ethical approval or consent to participate was necessary. Still for publication of the case the authors requested an ethical approval, which is available for inspection for the editors. The study was approved by the ethical committee of the Atomic Energy Commission, Damascus, Syria. The committee’s reference number is 4130/2015.

Author details
1Molecular Biology and Biotechnology Department, Human Genetics Div., Atomic Energy Commission of Syria, P.O. Box 6091, Damascus, Syria. 2Jena University Hospital, Institute of Human Genetics, Kollegienstrasse 10, D-07743 Jena, Germany. 3Molecular Biology and Biotechnology Department, Mammalian Biology Div., Flow-cytometry Lab, Atomic Energy Commission of Syria, P.O. Box 6091, Damascus, Syria.

Received: 29 September 2016 Accepted: 26 February 2017
Published online: 07 April 2017

References
1. Heim S, Mitelman F. Cancer Cytogenetics. 3rd ed. Hoboken: Wiley-Blackwell Publishers; 2009.
2. Schmiegelow K, Forestier E, Hellebostad M, Heyman M, Kristinsson J, Söderhall S, Taskinen M. Nordic Society of Paediatric Haematology and Oncology. Long-term results of NOPHO ALL-92 and ALL-2000 studies of childhood acute lymphoblastic leukemia. Leukemia. 2010;24:345–54.
3. Borowitz MJ, Hunger SP, Carroll AJ, Shuster JJ, Pullen J, Steuber CP, Cleary ML. Predictability of the t(1;19)(q21p13) from surface antigen phenotype: implication for screening cases of childhood acute lymphoblastic leukemia for molecular analyses: a Pediatric Oncology Group Study. Blood. 1993;83:1086–91.
4. Troussard X, Rimokh R, Valensi F, Leboeuf D, Fenneteau O, Guttard AM, Manel AM, Schilling F, Leglise C, Bizard A, et al. Heterogeneity of t(1;19)(q21;p13) acute leukemias. French Haematological Cytology Group. Br J Haematol. 1995;89:516–26.
5. Aspland SE, Bendall HH, Munce C. The role of E2A-PBX1 in leukemiaogenesis. Oncogene. 2001;20:5708–17.
6. Barber KE, Harrison CJ, Broadfield ZJ, Stewart AR, Wright SL, Martineau M, Srefford JC, Mooman AV. Molecular cytogenetic characterization of TCF3 (E2A)/19p13.3 rearrangements in B-cell precursor acute lymphoblastic leukemia. Genes Chromosomes Cancer. 2007;46:478–86.
7. Boomter T, Varella-Garcia M, McGavran L, Meltesen L, Olsen AS, Hunger SP. Detection of E2A translocations in leukemias via fluorescence in situ hybridization. Leukemia. 2001;15:95–102.
8. Brambilla F, Mosna G, Colombo M, Rivolta A, Caslini C, Minuzzo M, Giudici G, Mizzi L, Biondi A, Privitera E. Identification of a novel molecular partner of the E2A gene in childhood leukemia. Leukemia. 1999;13:369–75.
9. Crist WM, Carroll AJ, Shuster JJ, Behm FG, Whitehead M, Vietti TJ, Look AT, Mahoney D, Ragab A, Pullen DJ, et al. Poor prognosis of children with pre-B acute lymphoblastic leukemia is associated with the 1(1;19)(q23;p13). A pediatric Oncology Group Study. Blood. 1990;76:117–22.
10. Al-achkar W, Wafa A, Nweder M. A complex translocation t(5;9;22) in Philadelphia cells involving the short arm of chromosome 5 in a case of chronic myelogenous leukemia. J Exp Clin Cancer Res. 2007;26:411–5.

11. Shaffer LG, McGowan-Joran J, Schmid MS. ISCN 2013. An International System of Human Cytogenetic Nomenclature. Unionville: Karger Publications, Inc; 2013.

12. Liehr T, Helle A, Starke H, Rubtsov N, Trifonov V, Masek K, Weise A, Kuechler A, Claussen U. Microradioscoped based high resolution multicolor banding for all 24 human chromosomes. Int J Mol Med. 2002;9:335–9.

13. van Dongen JJ, MacIntyre EA, GAB J, Delabesse E, Rossi V, Saglio G, Gattardi E, Rambaldi A, Dotti G, Griesinger F, Panea A, Gameiro P, Diaz MG, Malec M, Langerak AW, San Miguel JF, Biondi A. Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. Leukemia. 1999;13:1901–28.

14. Mitelman F, Johansson B, Winters F, editors. Mitelman database of chromosome aberrations and gene fusions in cancer (2015). http://cgap.nci.nih.gov/Chromosomes/Mitelman. Accessed 20 Sep 2015.

15. Heim S, Mitelman F. Acute lymphoblastic leukemia. In: Heim S, Mitelman F, editors. Cancer Cytogenetics. 2nd ed. New York: Wiley-Liss; 1995. p. 180.

16. Pui CH, Raimondi SC, Hancock ML, Rivera GK, Ribeiro RC, Mahmoud HH, Heim S, Mitelman F. Acute lymphoblastic leukemia. In: Heim S, Mitelman F, editors. Mitelman database of chromosome aberrations and gene fusions in cancer (2015). http://cgap.nci.nih.gov/Chromosomes/Mitelman. Accessed 20 Sep 2015.

17. Yang YM, Bost F, Charbono W, Dean N, McKay R, Rhim JS, Depatie C, Delaney JR, Mlodzik M. TGF-beta activated kinase-1: new insights into the function of TGF-beta-activated kinase 1 and mitogenactivated protein kinase kinase 3. Mol Biol Cell. 2003;14:529–38.

18. Shapira M, Ben-Izhak O, Linn S, Futerman B, Minkov I, Hershko DD. The clinical significance of translocation t(1;19) in childhood acute lymphoblastic leukemia: a report from the Children’s Cancer Group. J Clin Oncol. 1998;16:327–35.

19. Jeha S, Pei D, Raimondi SC, Onciu M, Campana D, Cheng C, Sandlund JT, Ribeiro RC, Rubin JE, Howard SC, Downing JR, Evans WE, Relling MV, Pui CH. Increased risk for CNS relapse in pre-B cell leukemia with t(1;19)(PBX1-TCF3). Leukemia. 2003;17:406–9.